Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://davidz427vag2.evawiki.com/user